

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549  
**FORM 13F**

OMB APPROVAL

OMB Number:	3235-0006
Estimated average burden hours per response:	23.8

**FORM 13F COVER PAGE**

Report for the Calendar Year or Quarter Ended: 06-30-2023

Check here if Amendment  Amendment Number:  
This Amendment (Check only one.):  is a restatement.  
 adds new holdings entries.

**Institutional Investment Manager Filing this Report:**

Name: Carlyle Group Inc.  
Address: C/O THE CARLYLE GROUP  
1001 PENNSYLVANIA AVENUE, N.W.  
WASHINGTON, DC 20004  
Form 13F File Number: 028-15025  
CRD Number (if applicable): 111,128  
SEC File Number (if applicable): 801-52462

**The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.**

Person Signing this Report on Behalf of Reporting Manager:

Name: Jeffrey W. Ferguson  
Title: General Counsel  
Phone: 202-729-5626

**Signature, Place, and Date of Signing:**

/s/ Jeffrey W. Ferguson                  Washington, DC                  08-04-2023  
[Signature]                                  [City, State]                          [Date]

Explanatory Note 1: AlpInvest Partners B.V. is an indirectly wholly owned investment adviser of The Carlyle Group Inc. However, The Carlyle Group Inc. does not participate in any investment decision-making of AlpInvest Partners B.V. -- Explanatory Note 2: On August 1, 2022, The Carlyle Group Inc. completed its acquisition of the Abingworth group, a life sciences investment firm. As a result of the acquisition, Abingworth LLP has become a relying advisor of Carlyle Investment Management L.L.C. Abingworth Management Inc. is de-registering as an investment adviser with the United States Securities and Exchange Commission.

**Report Type (Check only one.):**

- 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)  
 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)  
 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)

**List of Other Managers Reporting for this Manager:  
[If there are no entries in this list, omit this section.]**

Form 13F                  Name

**Form 13F Summary Page****Report Summary:**

Number of Other Included Managers: 3  
Form 13F Information Table Entry Total: 27  
Form 13F Information Table Value Total: 2,807,308,291  
(round to  
nearest  
dollar)

**List of Other Included Managers:**

Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.

[If there are no entries in this list, state "NONE" and omit the column headings and list entries.]

No.	Name	Form 13F File Number	CRD No. (if applicable)	SEC File No. (if applicable)	CIK
1	Abingworth LLP	028-14285	000163213	802-75741	0001397144
2	Carlyle Investment Management LLC	028-12429	000111128	801-52462	0001354120
3	CIM Global, L.L.C.	028-15024	000114795		0001555793

---

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 13F**

OMB APPROVAL

OMB Number: 3235-0006  
 Estimated average burden  
 hours per response: 23.8

**FORM 13F INFORMATION TABLE**

COLUMN 1	COLUMN 2	COLUMN 3	COLUMN 4	COLUMN 5	COLUMN 6	COLUMN 7	COLUMN 8					
NAME OF ISSUER	TITLE OF CLASS	CUSIP	FIGI	VALUE	SHRS OR	SH/	PUT/	INVESTMENT	OTHER	VOTING AUTHORITY		
				(to the nearest dollar)	PRN	AMT	PRN	CALL	DISCRETION	MANAGER	SOLE	SHARED
Adicet Bio Inc	Com	007002108		5,119,232	2,115,385	SH		DFND	1	0	2,115,385	0
Aeglea Biotherapeutics Inc	Com	00773J103		108,225	240,500	SH		DFND	1	0	240,500	0
CubeSmart	Com	229663109		9,847,530	220,500	SH		DFND	2	0	220,500	0
Effector Therapeutics Inc	Com	28202V108		3,954,133	4,822,114	SH		DFND	1	0	4,822,114	0
Excicure Inc	Com New	30205M200		368,943	281,636	SH		DFND	1	0	281,636	0
GDS Hldgs Ltd	Sponsored Ads	36165L108		44,758,142	4,072,624	SH		DFND	2,3	0	4,072,624	0
Getty Images Holdings Inc	CI A Com	374275105		48,684,344	9,976,300	SH		DFND	2	0	9,976,300	0
Hillevax Inc	Com	43157M102		31,530,035	1,838,486	SH		DFND	1	0	1,838,486	0
Invitation Homes Inc	Com	46187W107		16,426,000	477,500	SH		DFND	2	0	477,500	0
Jasper Therapeutics Inc	Com	471871103		11,828,553	8,761,891	SH		DFND	1	0	8,761,891	0
Meta Data Limited	Sponsored Ads	68276W400		336,408	314,400	SH		DFND	2,3	0	314,400	0
MKS Instrs Inc	Com	55306N104		146,581,546	1,355,981	SH		DFND	2,3	0	1,355,981	0
MKS Instrs Inc	Com	55306N104		229,901,783	2,126,751	SH		DFND	2	0	2,126,751	0
Molecular Templates Inc	Com	608550109		92,000	200,000	SH		DFND	1	0	200,000	0
Nucana Plc	Sponsored Adr	67022C106		2,600,000	3,333,333	SH		DFND	1	0	3,333,333	0
Paratek Pharmaceuticals Inc	Com	699374302		2,300,900	1,041,131	SH		DFND	1	0	1,041,131	0
Phathom Pharmaceuticals Inc	Com	71722W107		50,074,291	3,496,808	SH		DFND	1	0	3,496,808	0
Quidelortho Corp	Com	219798105		1,032,450,763	12,460,183	SH		DFND	2	0	12,460,183	0
Reneo Pharmaceuticals Inc	Com	75974E103		17,678,168	2,698,957	SH		DFND	1	0	2,698,957	0
Seacor Marine Hldgs Inc	Com	78413P101		15,020,895	1,314,164	SH		DFND	2	0	1,314,164	0
Smart Sh Global Ltd	Ads	83193E102		4,689,593	4,810,209	SH		DFND	2,3	0	4,810,209	0
Soleno Therapeutics Inc	Com	834203309		5,094,385	1,201,506	SH		DFND	1	0	1,201,506	0
Spruce Biosciences Inc	Com	85209E109		6,227,514	2,896,518	SH		DFND	1	0	2,896,518	0

Vera Therapeutics Inc	Cl A	92337R101	38,766,065	2,416,837	SH	DFND	1	0	2,416,837	0
Verona Pharma Plc	Sponsored Ads	925050106	51,877,825	2,457,500	SH	DFND	1	0	2,457,500	0
Vitru Ltd	Com	G9440D103	100,130,930	6,246,471	SH	DFND	2,3	0	6,246,471	0
ZoomInfo Technologies Inc	Common Stock	98980F104	930,860,088	36,662,469	SH	DFND	2	0	36,662,469	0